RANI Investment Analysis: A platform play disrupting injectable paradigms with a ‘robotic capsule’ for oral biologics
RANI Investment Analysis: A platform play disrupting injectable paradigms with a ‘robotic capsule’ for oral biologics※ Rani Therapeutics (RANI) is a clinical-stage biotech developing a robotic capsule platform to deliver biologics orally. Core value drivers are clinical data (safety/PK/PD), indication expandability, manufacturing & supply (CMC) scale-up, partnerships/non-dilutive funding, cash r..
ARTV Investment Analysis: Clinical signals from immuno-oncology & cell-therapy platforms—and non-dilutive capital—will determine a valuation re-rating
ARTV Investment Analysis: Clinical signals from immuno-oncology & cell-therapy platforms—and non-dilutive capital—will determine a valuation re-rating※ Ativa Biotherapeutics (ARTV) is a clinical-stage biotech developing a pipeline based on immuno-oncology/cell-therapy platforms. Topline data, regulatory designations, partnerships/milestone inflows, cash runway, and dilution management are the co..
GNPX Investment Analysis: A clinical-stage biotech targeting NSCLC & diabetic complications with the ONCOPREX gene-delivery platform
GNPX Investment Analysis: A clinical-stage biotech targeting NSCLC & diabetic complications with the ONCOPREX gene-delivery platform※ Genprex (GNPX) is a clinical-stage biotech leveraging the non-viral gene delivery platform ONCOPREX® to address high-unmet-need indications such as non–small cell lung cancer (NSCLC). Key momentum drivers are progress in combination therapy trials, regulatory & fi..